Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon‐like peptide‐1 receptor agonist therapy in UK primary care: A retrospective, real‐world study
Diabetes Obesity and Metabolism2025Vol. 27(4), pp. 2086–2095
Citations Over TimeTop 10% of 2025 papers
Kunal Gulati, Katrien Wijndaele, Joanne Webb, Lill‐Brith von Arx, Monica Seif, Thomas Jennison, Antonia Geneidat, R Wild, Robert Wood, Kamlesh Khunti
Abstract
Two thirds of T2D patients receiving QW injectable GLP-1 RA for 6 months did not attain target HbA1c < 7%, and less than half and one-quarter of patients achieved ≥5% and ≥10% weight loss, respectively. Results suggest an unmet need for better clinical management of T2D in UK primary care.
Related Papers
- → Investigating lay beliefs regarding the effect of weight loss on health(2020)14 cited
- → Weight loss history as a predictor of weight loss: results from Phase I of the weight loss maintenance trial(2012)29 cited
- → Is Type 2 Diabetes in Adults Associated With Impaired Capacity for Weight Loss?(2017)7 cited
- → Dual Receptor Agonist for Type 2 Diabetes(2018)1 cited
- Editorial Note on Journal of Nutrition and Weight Loss (2020)(2020)